Skip to main content

New Trends in Thromboxane and Prostacyclin Modulators

Buy Article:

$63.00 plus tax (Refund Policy)

Thromboxane A 2 (TXA 2 ) and prostacyclin (PGI 2 ) are two labile products formed from arachidonic acid by the way of cyclooxygenase. An overproduction of thromboxane A 2 has been detected in a series of diseases whereby this prostanoid is assumed to contribute to the underlying pathomechanisms by its potent stimulation of platelet aggregation and smooth muscle contraction. This increased TXA 2 biosynthesis is frequently accompanied by a stimulation of prostacyclin formation which is one of the most potent inhibitors of platelet aggregation and smooth muscle contraction. Therefore, TXA 2 prostaglandin endoperoxide H 2 receptor antagonists, thromboxane synthase inhibitors and drugs which combine both activities have been developed with the aim to suppress the formation and/or the action of thromboxane A 2 . Since prostacyclin has been demonstrated to counterbalance the pathological effects of TXA 2 , several PGI 2 agonists have also been developed. This review will highlight the evolution and some of the latest findings in the field of prostacyclin and thromboxane A 2 modulators mainly those which are under clinical evaluation or marketed.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: Combined thromboxane A2 receptor antagonists; Non Prostanoid thromboxane A2 receptor antagonists; Prostanoid thromboxane A2 receptor antagonists; TXA2 PGH2 receptor antagonists TXRAs; TXA2 biosynthesis; TXSIs; prostacylin modulators; prostaglandin D2; prostaglandin E2; prostaglandin F2; prostaglandin G2; prostaglandin H2; prostaglandin endoperoxide H2 receptor antagonists; sulotroban; thormboxane synthase inhibitors; thromboxane A2 TXA2

Document Type: Review Article

Publication date: 2000-06-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more